About this Research Topic
There is a dire need to capitalize on the body's immune system to recognize and combat malignancies. In this context, this special issue will discuss major challenges limiting the outcome of cancer-directed immune interventions. The primary emphasis of this special issue would be to discuss possible modalities for rendering cancer immunotherapy more effective as a better and more affordable treatment option for cancer patients. The immune system's ability to distinguish between normal and abnormal cells is crucial, yet cancer cells often evade detection through various mechanisms. Given these intrinsic factors, tailoring immune-therapeutics approaches to augment immune response against cancer is paramount. This can be achieved by employing several strategies like immune checkpoint inhibitors, which release the brakes on immune cells, and CAR T-cell, CAR-NK cells, and CAR-Macrophage-based therapy, which involves better engineering patients' cells to target cancer cells. These therapies have shown remarkable success in treating various types of cancer, leading to prolonged survival and, in some cases, complete remission. However, challenges remain, including understanding resistance mechanisms, managing side effects, and ensuring broader applicability across diverse cancer types.
The major goal of this Research Topic is to collect various hypotheses and research-based evidence as a herbarium, which can benefit the oncology society/community. The central theme of this Research Topic is to mail down various intrinsic mechanisms of how tumors evade immune detection and destruction. This area is still in its infancy and needs better definitions for unraveling innovative therapeutic strategies such as immune checkpoint inhibitors, CAR T-cell therapy, CAR-NK cells, CAR-Macrophage therapy, and cancer vaccines, alongside their clinical outcomes in suitable concoctions. Another primary scope of this Research Topic would be to discuss various translational approaches crucial in minimizing the gap between the bench and bedside aspects and facilitating the development of new treatment modalities. Additionally, these particular issues would enhance our understanding of resistance mechanisms to current immunotherapies and help identify various biomarkers for personalized medicine, which are critical areas of focus. The above approaches would improve patient outcomes and advance the field toward more effective, targeted cancer treatments.
We welcome the submission of Original Research, Reviews, Mini-Review, Methods, Case reports, Clinical Trial Reports, and Perspective articles that cover, but are not limited to the following areas:
• The mechanisms of immune recognition and evasion by cancer cells
• The development of novel immunotherapeutic agents
• Clinical trial outcomes
• Biomarkers for predicting therapy response
• Strategies to overcome resistance to immunotherapy
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
The major goal of this Research Topic is to collect various hypotheses and research-based evidence as a herbarium, which can benefit the oncology society/community. The central theme of this Research Topic is to mail down various intrinsic mechanisms of how tumors evade immune detection and destruction. This area is still in its infancy and needs better definitions for unraveling innovative therapeutic strategies such as immune checkpoint inhibitors, CAR T-cell therapy, CAR-NK cells, CAR-Macrophage therapy, and cancer vaccines, alongside their clinical outcomes in suitable concoctions. Another primary scope of this Research Topic would be to discuss various translational approaches crucial in minimizing the gap between the bench and bedside aspects and facilitating the development of new treatment modalities. Additionally, these particular issues would enhance our understanding of resistance mechanisms to current immunotherapies and help identify various biomarkers for personalized medicine, which are critical areas of focus. The above approaches would improve patient outcomes and advance the field toward more effective, targeted cancer treatments.
We welcome the submission of Original Research, Reviews, Mini-Review, Methods, Case reports, Clinical Trial Reports, and Perspective articles that cover, but are not limited to the following areas:
• The mechanisms of immune recognition and evasion by cancer cells
• The development of novel immunotherapeutic agents
• Clinical trial outcomes
• Biomarkers for predicting therapy response
• Strategies to overcome resistance to immunotherapy
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords: Cancer, Immune Plasticity, immune recognition, immune evasion, Immunotherapy, immunotherapeutic agents, Tumor Diseases
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
